中信证券保荐国产吸入制剂龙头企业长风药业登陆港交所

中信证券发布
Oct 08, 2025

2025年10月8日,长风药业股份有限公司(以下简称长风药业,2652.HK)成功于香港联交所主板上市,发行规模约6.08亿港币。中信证券担任牵头保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。香港市场吸入制剂第一股香港公开发售认购倍数达6,697.80倍,斩获港股医疗健康行业IPO公开认购倍数历史第一2025年以来上市的13单港股生物医药IPO中,中信证券以保荐人身份参与8单...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10